Literature DB >> 7953503

Mixed expired nitric oxide in primary pulmonary hypertension in relation to lung diffusion capacity.

G Cremona1, T Higenbottam, C Borland, B Mist.   

Abstract

The mixed expired nitric oxide (NO) production of the lungs of patients with primary pulmonary hypertension (PPH) and normal subjects was measured to determine the relationship between NO production and the diffusion capacity of the lung (KCO). Expired air was collected from eight patients with PPH and 20 healthy volunteers for analysis by a chemiluminescent analyser. Mean pulmonary artery pressure in the PPH patients was 59.5 +/- 6.45 mmHg and their mean cardiac output was 2.95 +/- 0.35 l/min. All patients and subjects underwent measurements of FEV1, VC and KCO. The rate of production of NO in mixed exhaled air was lower in the PPH group compared to the controls (2.85 +/- 0.7 vs. 4.69 +/- 0.35 nM/min; p < 0.05). There was a good correlation of expired NO with the KCO (r = 0.7; n = 30; p < 0.001). When corrected, KCO differences in exhaled NO were not significant (p = 0.09). We conclude that the low exhaled NO observed in PPH patients is a reflection of the reduced blood capillary volume in these patients rather than a decreased basal production of NO.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7953503

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  7 in total

1.  Measurement of endogenous nitric oxide production.

Authors:  E Bruckheimer; S Rimar; A B Dubois; J S Douglas
Journal:  J Clin Monit Comput       Date:  2000-01       Impact factor: 2.502

2.  Increased expired NO and roles of CO2 and endogenous NO after venous gas embolism in rabbits.

Authors:  Per Agvald; L Christofer Adding; Kristofer F Nilsson; Lars E Gustafsson; Dag Linnarsson
Journal:  Eur J Appl Physiol       Date:  2006-04-21       Impact factor: 3.078

3.  Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study.

Authors:  Nilay Orak Akbay; Zuleyha Bingol; Esen Kiyan; Ekrem Bilal Karaayvaz; Ahmet Kaya Bilge; Halim Issever; Gulfer Okumus
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

Review 4.  Protein O-GlcNAcylation in cardiovascular diseases.

Authors:  Hui-Fang Wang; Yi-Xuan Wang; Yu-Ping Zhou; Yun-Peng Wei; Yi Yan; Ze-Jian Zhang; Zhi-Cheng Jing
Journal:  Acta Pharmacol Sin       Date:  2022-07-11       Impact factor: 7.169

5.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Sanjiv Kumar; Shruti Sharma; Saurabh Aggarwal; Frank Schneider; Danny Jonigk; Stephen M Black; Stevan P Tofovic
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

6.  Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension.

Authors:  J K Mansoor; Edward S Schelegle; Cristina E Davis; William F Walby; Weixiang Zhao; Alexander A Aksenov; Alberto Pasamontes; Jennifer Figueroa; Roblee Allen
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

7.  Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension.

Authors:  Giovanna Elisiana Carpagnano; Alessandro Radaeli; Donato Lacedonia; Michele Correale; Giuseppe Carpagnano; Antonio Palmiotti; Maria Pia Foschino Barbaro; Matteo Di Biase; Natale Brunetti; Giulia Scioscia; Mario Malerba
Journal:  Biomed Res Int       Date:  2018-08-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.